Search This Blog

Wednesday, September 7, 2022

Seres Submits Application for Work on C. difficile Therapy

 – Investigational therapeutic SER-109 has the potential to become the first-ever FDA-approved oral microbiome therapeutic 

– Anticipated product launch in the first half of 2023 

https://finance.yahoo.com/news/seres-therapeutics-announces-completion-rolling-110000716.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.